(Total Views: 203)
Posted On: 01/22/2021 4:58:44 PM
Post# of 281
NetworkNewsBreaks – Predictive Oncology (NASDAQ: POAI) Closes Registered Direct Offering for $2.2 Million, Announces $4.1 Million Registered Direct Offering
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has closed on its previously announced registered direct offering; the company also announced that it has completed definitive agreements with a number of institutional and accredited investors for a registered direct offering. According to the announcement, POAI’s previously announced offering closed with 2,200,000 shares of common stock being sold, at a price of $1.00 per share. The gross proceeds for POAI was $2.2 million, with the company planning to use the funds for working capital purposes. Placement agent fees and other expenses related to the closing will be deducted from those proceeds. The company also announced that, in a concurrent private placement, it had issued to the same investors unregistered warrants to purchase up to 1,100,000 more shares of common stock; the exercise price for those will also be $1.00 per share. The cost for all shares was priced at-the-market under Nasdaq Rules. The newly announced registered direct offering comprises the issuance and sale of approximately 3,414,970 shares of POAI common stock. The offering is at a purchase price of $1.20 per share, also priced at-the-market under Nasdaq rules; the offering should result in gross proceeds of approximately $4.1 million for Predictive Oncology. All shares are part of POAI’s previously announced registered direct offering, filed with the Securities and Exchange Commission (“SEC”) in October 2019 with an effective date of Dec. 19, 2019.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has closed on its previously announced registered direct offering; the company also announced that it has completed definitive agreements with a number of institutional and accredited investors for a registered direct offering. According to the announcement, POAI’s previously announced offering closed with 2,200,000 shares of common stock being sold, at a price of $1.00 per share. The gross proceeds for POAI was $2.2 million, with the company planning to use the funds for working capital purposes. Placement agent fees and other expenses related to the closing will be deducted from those proceeds. The company also announced that, in a concurrent private placement, it had issued to the same investors unregistered warrants to purchase up to 1,100,000 more shares of common stock; the exercise price for those will also be $1.00 per share. The cost for all shares was priced at-the-market under Nasdaq Rules. The newly announced registered direct offering comprises the issuance and sale of approximately 3,414,970 shares of POAI common stock. The offering is at a purchase price of $1.20 per share, also priced at-the-market under Nasdaq rules; the offering should result in gross proceeds of approximately $4.1 million for Predictive Oncology. All shares are part of POAI’s previously announced registered direct offering, filed with the Securities and Exchange Commission (“SEC”) in October 2019 with an effective date of Dec. 19, 2019.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
